Futurity

Share

Futurity

 •  November 20, 2017

More than 90 percent of new drugs received funding from the National Institutes of Health. Now, US President Donald Trump’s proposed budget calls for cutting the NIH budget by 21 percent, or about $7.2 billion. “Cutting the NIH budget could dismantle our ability to address real problems,” says Michael S. Kinch, a professor of biochemistry and...

Futurity

 •  September 22, 2017

A new gene therapy could inhibit or reverse multiple sclerosis, new research using mouse models suggests. By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. Likewise, the treatments produced near-complete remission in the animal models. The findings could lead...

Futurity

 •  September 13, 2017

A new drug is effective against non-severe cases of malaria, clearing the parasite responsible for the disease within a week, a new study reports. The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New...

Futurity

 •  August 7, 2017

Researchers have developed a new method for evaluating drug safety that can detect stress on cells at earlier stages than current methods, which mostly rely on detecting cell death. The new method uses a fluorescent sensor that is turned on in a cell when misfolded proteins begin to aggregate—an early sign of cellular stress. The method can be...

Futurity

 •  May 22, 2017

A small clinical trial suggests that some patients with severe asthma may benefit from treatment with a targeted cancer drug. The findings show that imatinib (brand name Gleevec), commonly prescribed to treat chronic myeloid leukemia, also targets specific immune cells known to drive inflammation in the lungs. “We are still in the early phase of...